Cancer Letters
Volume 225, Issue 1 , Pages 61-74, 8 July 2005

Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines

  • Jia-Lin Yang

      Affiliations

    • Department of Surgery and Surgical Oncology Research Group, Prince of Wales Clinical School, University of New South Wales, Barker Street, Randwick, Sydney, NSW 2031, Sydney, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 93822624; fax: +61 2 93822629.
    • ,
  • Xian-Jun Qu

      Affiliations

    • Department of Pharmacology, College of Pharmacy, Shandong University, Jinan, People's Republic of China
    • ,
  • Pamela J. Russell

      Affiliations

    • Oncology Research Centre, Prince of Wales Hospital, University of New South Wales, Sydney, Australia
    • ,
  • David Goldstein

      Affiliations

    • Department of Medical Oncology, Prince of Wales Hospital, University of New South Wales, Sydney, Australia

Received 20 August 2004; received in revised form 20 November 2004; accepted 24 November 2004.

Abstract 

Interferon-alpha (IFNα) treatment is associated with up-regulation of epidermal growth factor receptor (HER1/EGFR) expression and marked growth inhibition while maintaining the sensitivity of the target colon cancer cells to epidermal growth factor (Gut 2004;53:123). We aimed to determine the effect of combining IFNα and Erlotinib (an HER1/EGFR inhibitor) on colon cancer cell line growth. Crystal-violet staining and flow cytometry were used to assess cell proliferation and expression of HER1/EGFR. IFNα pre-treatment followed by a combination of IFNα plus Erlotinib significantly enhanced the sensitivity of 7/9 of colon cancer cell lines by 7–43%. This approach may have clinical implications for improving treatment based on targeting of HER1/EGFR.

Keywords: Interferon-alpha, HER1/EGFR inhibitor, Erlotinib, Colon cancer cell line

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(04)00936-X

doi:10.1016/j.canlet.2004.11.041

Cancer Letters
Volume 225, Issue 1 , Pages 61-74, 8 July 2005

Article Tools

* Image Usage & Resolution